U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07073638) titled 'Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis' on July 09.
Brief Summary: A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
Study Start Date: Oct. 06, 2025
Study Type: INTERVENTIONAL
Condition:
Pulmonary Tuberculoses
Intervention:
DRUG: RESP30TB
Nitric Oxide agent
DRUG: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg ...